05/16/2024 | Press release | Distributed by Public on 05/16/2024 04:01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) |
||
Delaware |
001-33407 |
41-1458152 |
2401 Elliott Avenue, Suite 320 Seattle, Washington |
98121 |
|
(Address of principal executive offices) |
(Zip code) |
Johan (Thijs) Spoor, CEO |
(206) 676-0900 |
|
(Name and telephone number, including area code, of the person to contact in connection with this report.) |
Check the appropriate box to indicate the rule pursuant to which this form is being filed:
☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2023.
☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended __________.
Introduction
This Specialized Disclosure Report on Form SD (Form SD) of Perspective Therapeutics, Inc. (Perspective Therapeutics, the Company, or we) for the year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). Numerous terms in this Form SD are defined in the Rule and the reader is referred to that source and to SEC Release No. 34-67716 issued by the Securities and Exchange Commission on August 22, 2012, as amended, for such definitions.
We are a radiopharmaceutical company that is developing the next generation of precision-targeted alpha therapies that have the potential to treat a large population of cancer patients across multiple tumor types and until April 12, 2024, we manufactured and marketed seed brachytherapy for various cancers. Our brachytherapy seeds contained a small amount of gold that is necessary to the functionality or production of those products. Our brachytherapy seeds were manufactured in Perspective Therapeutics' own facility. Although our brachytherapy seeds contained a small amount of gold, Perspective Therapeutics does not purchase ore or unrefined conflict minerals from mines and is many steps removed in the supply chain from the mining of the conflict minerals. We historically have purchased the gold used in our products from a single supplier. This supplier is in the best position in the total supply chain to know the origin of the gold we use. We rely on this supplier to assist with our reasonable country of origin inquiry for the gold contained in the materials which it supplies to us.
Section 1- Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Conflict Minerals Disclosure
This Form SD of Perspective Therapeutics is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2023 to December 31, 2023.
The Company manufactured products (until the divestiture of that business line on April 12, 2024) for which a Conflict Mineral, gold, is necessary to the functionality or production of those products. The Company has conducted a good faith reasonable country of origin inquiry that was reasonably designed to determine whether any of the Conflict Minerals used in its products originated in the Democratic Republic of Congo or an adjoining country (the Covered Countries) and whether any of the Conflict Minerals are from recycled or scrap sources.
For the 2023 reporting year, we contacted our single direct supplier of gold to obtain country of origin information for the gold in our brachytherapy seeds. Our supplier certified that all gold purchased by the Company in 2023 was from sources outside of the Covered Countries.
Conclusion
Based on this reasonable country of origin inquiry, the Company determined that it has no reason to believe that any of the Conflict Minerals used in its products may have originated in the Covered Countries.
Website Disclosure
This Form SD is publicly available at perspectivetherapeutics.com/investors/sec-filings as well as the SEC's EDGAR database at www.sec.gov. The content of any website referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
PERSPECTIVE THERAPEUTICS, INC. |
|||
Date: |
May 15, 2024 |
By: |
/s/ Johan (Thijs) Spoor |
Johan (Thijs) Spoor |
3